# A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

> **NCT04853498** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 192 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** TQB3720

## Key facts

- **NCT ID:** NCT04853498
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-09
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 192 (ACTUAL)
- **Why stopped:** Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853498, "A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04853498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*